Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Axim Biotechnologies (OTC: $AXIM) Discusses AXIM's proprietary #cannabinoid research and development
Delta, Kelowna, BC - October 5, 2018 (Investorideas.com Newswire) https://www.investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Axim Biotechnologies (OTC: $AXIM) Discusses AXIM's proprietary #cannabinoid research and development
Hear Investor ideas cannabis potcast on iTunes
Investor Ideas talks with Dr. George E. Anastassov, CEO of Axim Biotechnologies Inc. (OTC: AXIM) regarding AXIM's proprietary, controlled-release functional chewing gum containing full-spectrum hemp oil-derived CBD, which will soon be available for consumers in Canada, Australia, New Zealand and South Korea, and the cannabis pharmaceutical market.
In America, the formula can be found in AXIM's flagship product, MedChew® Rx chewing gum currently in clinical trials to treat patients with Multiple Sclerosis and AXIM's OTC cannabis chewing gum, CanChew® with 50 mg of CBD per piece. Currently, AXIM's CanChew® gum is the world's only patented controlled-release cannabis chewing gum.
George discusses the DEA's recent decision to make Epidiolex, of GW Pharmaceuticals (NASDAQ:GWPH), a Schedule V controlled substance and how that affects both AXIM and the cannabis pharmaceutical market as a whole.
He also discusses some of the roadblocks facing the pharmaceutical side of cannabis today and where the market is heading.
About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (OTC: AXIM) is an innovative biotechnology and pharmaceutical company focusing on research, development and production of cannabinoid-based pharmaceutical and nutraceutical products. AXIM's flagship products include MedChew® Rx, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS); MedChew® Dronabinol which will undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; and CanChew® RL, which will undergo clinical trials for treatment of restless leg syndrome. At AXIM, we prioritize the wellbeing of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an Investor ideas member, plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move. Learn more https://www.investorideas.com/membership/
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column and the Cleantech and Climate Change Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Learn more about Investor ideas podcast and news publication services and costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
